Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v2.4.0.6
Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Jun. 30, 2012
Jul. 02, 2011
Cash flows from operating activities:    
Net income $ 21,870 $ 20,207
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 3,576 3,368
(Gain) Loss on disposal of assets (21) 69
Unrealized foreign exchange loss 15  
Provision for deferred income taxes 1 6
Allowance for doubtful accounts (15) 1
Stock-based compensation expense 1,157 829
(Increase) decrease in:    
Accounts receivable (5,494) (6,954)
Inventories (890) (1,276)
Income taxes receivable 120 671
Other current assets (304) (352)
Other assets 181 (318)
Increase (decrease) in:    
Accounts payable 403 1,827
Accrued expenses and other liabilities 2,834 3,526
Income taxes payable 342  
Other noncurrent liabilities 25 365
Net cash provided by operating activities 23,800 21,969
Cash flows from investing activities:    
Proceeds from sale of joint venture    1,451
Capital expenditures (4,752) (2,811)
Proceeds from dispositions 21 30
Purchases of marketable securities (12,251) (5,500)
Proceeds from sale of marketable securities 3,130 4,190
Net cash used in investing activities (13,852) (2,640)
Cash flows from financing activities:    
Proceeds from exercise of stock options   61
Proceeds from stock issued 333 281
Dividends to shareholders (7,769) (4,952)
Net cash used in financing activities (7,436) (4,610)
Effect of exchange rate changes on cash and cash equivalents (309) 1,795
Net increase in cash and cash equivalents 2,203 16,514
Cash and cash equivalents, beginning of period 51,262 33,206
Cash and cash equivalents, end of period 53,465 49,720
Cash Paid [Abstract]    
Income taxes 10,272 9,104
Supplemental disclosure of noncash transactions:    
Common stock issued for shared distribution through accrued expenses and other liabilities 4,407 2,412
Common stock issued for deferred director's compensation through other noncurrent liabilities $ 930